Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
EphB3
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "EphB3" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .
Cat. No.: HY-P5438
Cat. No.: HY-RS17657
Target:
Research Areas:
Ephb3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ephb3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-170517
CAS No.: 3065631-84-4
Target:
Research Areas:
PKMYT1-IN-8 (Compound 137) is the inhibitor for PKMYT1 with an IC50 of 9 nM. PKMYT1-IN-8 inhibits EPHB3, EPHA1, KIT, EPHB1, EPHA2, EPHA3, and EPHB2with IC50s of 1.79, 3.17, 4.29, 6.32, 6.83, 8.10, and 10.9 μM, respectively. PKMYT1-IN-8 inhibits the proliferation of cancer cell OVCAR3 with GI50 of 2.02 μM .
Cat. No.: HY-RS04435
Target:
Research Areas:
EPHB3 Human Pre-designed siRNA Set A contains three designed siRNAs for EPHB3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-146375
CAS No.: 2938227-14-4
Target:
Research Areas:
UniPR505 (Compound 14) is an EphA2 antagonist with an IC50 of 0.95 µM. UniPR505 displays anti-angiogenic properties .
Cat. No.: HY-RS24118
Target:
Research Areas:
Ephb3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ephb3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-136358
CAS No.: 1198408-39-7
Target:
Research Areas:
LDN-211904 is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab (HY-P9905) resistance in CRC .
Cat. No.: HY-121682
CAS No.: 61788-27-0
Target:
Research Areas:
N-(2-Chlorophenyl)-1H-indole-3-carboxamide (Compound 60) is a substituted derivative of the pyrazolo[1,5-a]pyridine core. N-(2-Chlorophenyl)-1H-indole-3-carboxamide does not exhibit EphB3 kinase inhibitory activity and can be used as a negative control compound .
Cat. No.: HY-P991975
Target:
Research Areas:
Cat. No.: HY-P702711
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: EphB3; EPH receptor B3; EK2; ETK2; HEK2; TYRO6
Species:
Source:
Cat. No.: HY-P705820
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: EphB3; EPH receptor B3; EK2; ETK2; HEK2; TYRO6
Species:
Source:
Cat. No.: HY-107460R
CAS No.: 1198408-78-4
Target:
Research Areas:
LDN-211904 oxalate (Standard) is the analytical standard of LDN-211904 (oxalate) (HY-107460). This product is intended for research and analytical applications. LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
